S&P 500   3,121.24 (+0.02%)
DOW   28,020.85 (+0.06%)
QQQ   202.85 (-0.03%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
T   39.42 (-0.23%)
ACB   2.43 (-10.97%)
F   8.95 (+0.00%)
BAC   32.94 (+0.03%)
DIS   148.67 (+2.76%)
S&P 500   3,121.24 (+0.02%)
DOW   28,020.85 (+0.06%)
QQQ   202.85 (-0.03%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
T   39.42 (-0.23%)
ACB   2.43 (-10.97%)
F   8.95 (+0.00%)
BAC   32.94 (+0.03%)
DIS   148.67 (+2.76%)
S&P 500   3,121.24 (+0.02%)
DOW   28,020.85 (+0.06%)
QQQ   202.85 (-0.03%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
T   39.42 (-0.23%)
ACB   2.43 (-10.97%)
F   8.95 (+0.00%)
BAC   32.94 (+0.03%)
DIS   148.67 (+2.76%)
S&P 500   3,121.24 (+0.02%)
DOW   28,020.85 (+0.06%)
QQQ   202.85 (-0.03%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
T   39.42 (-0.23%)
ACB   2.43 (-10.97%)
F   8.95 (+0.00%)
BAC   32.94 (+0.03%)
DIS   148.67 (+2.76%)
Log in

Alpine Immune Sciences Stock Price, Forecast & Analysis (NASDAQ:ALPN)

$2.60
-0.12 (-4.41 %)
(As of 11/18/2019 11:15 AM ET)
Today's Range
$2.33
Now: $2.60
$2.67
50-Day Range
$2.35
MA: $3.07
$4.14
52-Week Range
$2.25
Now: $2.60
$8.24
Volume1,200 shs
Average Volume33,921 shs
Market Capitalization$48.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$700,000.00
Book Value$3.22 per share

Profitability

Net Income$-36,490,000.00

Miscellaneous

Employees48
Market Cap$48.28 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.


Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) announced its quarterly earnings data on Wednesday, November, 13th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06. The biotechnology company earned $0.29 million during the quarter, compared to analyst estimates of $0.38 million. View Alpine Immune Sciences' Earnings History.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Alpine Immune Sciences.

What price target have analysts set for ALPN?

2 brokers have issued 12 month target prices for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $13.00. On average, they expect Alpine Immune Sciences' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 303.8% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.

What is the consensus analysts' recommendation for Alpine Immune Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

Press coverage about ALPN stock has trended very negative on Monday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Alpine Immune Sciences.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 27,400 shares, an increase of 86.4% from the September 30th total of 14,700 shares. Based on an average trading volume of 22,900 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.3% of the company's shares are sold short. View Alpine Immune Sciences' Current Options Chain.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Hikari Power Ltd (1.00%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC. View Institutional Ownership Trends for Alpine Immune Sciences.

Which major investors are buying Alpine Immune Sciences stock?

ALPN stock was acquired by a variety of institutional investors in the last quarter, including Hikari Power Ltd. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey and Mitchell Gold. View Insider Buying and Selling for Alpine Immune Sciences.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $2.60.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $48.28 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.View Additional Information About Alpine Immune Sciences.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  629
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel